A Multi-center Open Label Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib
R
Robert Fallon, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
1 years - 18 years
All
Phase
N/A
1 Location
Brief description of study
To evaluate the safety, efficacy and concentration of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to
Detailed description of study
To evaluate the safety, efficacy and concentration of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Leukemia,Bone Marrow Disease,Hematologic Disease,Neoplastic Process
-
Age: 1 years - 18 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: CAMN107A2203
